Using a cohort of 298 urothelial cancer patient treated with the PD-L1 blockade cancer immunotherapy agent atezolizumab, we found that PRLR showed significant gene expression differences between 68 responders and 230 non-responders (fold change = 1.5, moderated t-test P = 0.049; Fig. 3D). The gene discussed is PRLR; the disease is cancer.